A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …
Filed under: Uncategorized | Tagged: ADT, agent, androgen, cancer-specific, deprivation, exposure, Orange, prostate, survival | 2 Comments »
As our regular readers will be well aware, there have been a number of published papers suggesting associations between the use of statins and other lipid-lowering agents and risk for diagnosis with and progression of prostate cancer over time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: agent, lipid, lowering, Prevention, statin | 3 Comments »
According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: agent, imaging, MIP-1072, MIP-1095, MIP-1404 | Leave a comment »
According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 